Compare ADMA Biologics Inc (ADMA) vs Uber Technologies Inc (UBER) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Uber Technologies Inc — how do they compare? ADMA Biologics Inc trades at $9.25 (market cap $2.13B), while Uber Technologies Inc trades at $72.95 (market cap $151.31B). The key difference: Uber Technologies Inc is far larger — about 71× ADMA Biologics Inc's market cap. Which is the better fit depends on your goals.
| ADMA | UBER | |
|---|---|---|
Market Cap | $2.13B | $151.31B |
Sector | Health | Industrials |
52-Week High | $20.38 | $100.10 |
52-Week Low | $7.60 | $68.61 |
Enterprise Value | $2.20B | $157.63B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Uber (UBER) trades at $72.42, down 2.7% today, amid a bearish technical signal but strong fundamentals. The stock shows robust revenue growth, with 2025 revenue reaching $52.02 billion, and a net income margin of 15.91%. Recent news highlights strategic moves into autonomous vehicles, including robotaxi pilots in Madrid and Munich, while cost-cutting measures like HR layoffs aim to improve efficiency.
The outlook is mixed: analyst consensus is strongly bullish with a $109.25 price target, but technical indicators and projected 2026 cash flow decline pose risks. Key opportunities include expansion in autonomous driving partnerships; risks involve competitive pressures and execution challenges in new markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Uber Technologies Inc
Uber Technologies is a technology provider that matches riders with drivers, hungry people with restaurants and food delivery service providers, and shippers with carriers. The firm's on-demand technology platform could eventually be used for additional products and services, such as autonomous vehicles, delivery via drones, and Uber Elevate, which, as the firm refers to it, provides aerial ride-sharing. Uber Technologies is headquartered in San Francisco and operates in over 63 countries with over 110 million users that order rides or foods at least once a month. Approximately 76% of its gross revenue comes from ride-sharing and 22% from food delivery.
Read more on UBER →
